Amgen to invest $1 billion in production expansion at Holly Springs
US biotech giant Amgen (Nasdaq: AMGN) today revealed a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina, bringing the group’s planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
Amgen adds to Holly Spring’s status as an emerging biotech hot spot, joining other manufacturers CSL Seqirus and FujiFilm Diosynth. Like Amgen, FujiFilm this year announced a significant expansion to its own incoming Wake County site.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Robert Bradway, chairman and chief executive at Amgen. “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze